Northwest Biotherapeutics' DCVax for tumors shows positive Phase I/II results Northwest Biotherapeutics announced that, in the ongoing Phase I/II clinical trial of DCVax-Direct for all types of inoperable solid tumors, all 9 out of 9 patients who have received 4 of the 6 planned injections are showing tumor cell death, tumor shrinkage, substantial immune cell accumulation in their tumors and/or stabilization of their advanced cancer. In addition, in 3 of these 9 patients, biopsies now show no live tumor cells in the injected tumor. The company plans to report more details when the patients are further along in the treatment regimen.
News For NWBO From The Last 14 Days
Check below for free stories on NWBO the last two weeks.